as of 12-05-2025 3:45pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 2.0B | IPO Year: | N/A |
| Target Price: | $99.29 | AVG Volume (30 days): | 468.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $99.50 | Next Earning Date: | 11-07-2025 |
| Revenue: | $826,880,000 | Revenue Growth: | 48.87% |
| Revenue Growth (this year): | 43.41% | Revenue Growth (next year): | 9.66% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SR. VP, GENERAL COUNSEL & SEC.
Avg Cost/Share
$87.27
Shares
400
Total Value
$34,908.00
Owned After
75,274
SEC Form 4
SVP - CORP. DEV. & STRATEGY
Avg Cost/Share
$88.00
Shares
94
Total Value
$8,272.00
Owned After
158,490
SEC Form 4
Director
Avg Cost/Share
$86.88
Shares
8,643
Total Value
$750,903.84
Owned After
61,405
SEC Form 4
SVP - CORP. DEV. & STRATEGY
Avg Cost/Share
$89.07
Shares
14,642
Total Value
$1,304,162.94
Owned After
158,490
SEC Form 4
SR. VP, GENERAL COUNSEL & SEC.
Avg Cost/Share
$90.09
Shares
400
Total Value
$36,036.00
Owned After
75,274
SEC Form 4
SVP, CHIEF HR OFFICER
Avg Cost/Share
$98.04
Shares
1,000
Total Value
$98,040.00
Owned After
60,186
SEC Form 4
SR. VP, GENERAL COUNSEL & SEC.
Avg Cost/Share
$98.42
Shares
400
Total Value
$39,368.00
Owned After
75,274
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Nov 13, 2025 | Sell | $87.27 | 400 | $34,908.00 | 75,274 | |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | Nov 13, 2025 | Sell | $88.00 | 94 | $8,272.00 | 158,490 | |
| Walsh Patrick D | ANIP | Director | Nov 13, 2025 | Sell | $86.88 | 8,643 | $750,903.84 | 61,405 | |
| Gassert Chad | ANIP | SVP - CORP. DEV. & STRATEGY | Nov 12, 2025 | Sell | $89.07 | 14,642 | $1,304,162.94 | 158,490 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Oct 13, 2025 | Sell | $90.09 | 400 | $36,036.00 | 75,274 | |
| Davis Krista | ANIP | SVP, CHIEF HR OFFICER | Sep 19, 2025 | Sell | $98.04 | 1,000 | $98,040.00 | 60,186 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Sep 12, 2025 | Sell | $98.42 | 400 | $39,368.00 | 75,274 |
See how ANIP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.